Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0306900 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Po-Chieh Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Phenylthiohydantoin, Benzamides, Nitriles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Non-metastatic castration-resistant prostate cancer (nmCRPC) is an asymptomatic condition with the potential to progress to metastasis. Novel hormonal agents (NHAs) are currently considered the gold standard treatment for nmCRPC, offering significant survival benefits. However, further evidence is needed to determine whether there are differences in the performance of these drugs among Asian populations.
Methods
This retrospective analysis of nmCRPC patients aims to compare the efficacy and safety of three NHAs–apalutamide, darolutamide, and enzalutamide. Data were collected from two prominent prostate care centers in Taichung, Taiwan. Patient characteristics, treatment details, PSA responses, and adverse events were analyzed. Statistical comparisons were performed, and the study received Institutional Review Board approval.
Results
Total of 64 patients were recruited in this study, including 29 darolutamide, 26 apalutamide, and 9 enzalutamide patients. Baseline characteristics varied between the three patient groups, but the treatment response still revealed similar results. The apalutamide group experienced more adverse events, notably skin rash. Discontinuation rates due to adverse events differed among the groups, and patients receiving darolutamide were less likely to discontinue treatment.
Conclusion
This real-world study provides insights into NHA utilization in nmCRPC within the Taiwanese population. Adverse event profiles varied, emphasizing the need for individualized treatment decisions. The study underscores the importance of regional considerations and contributes valuable data for optimizing treatment outcomes in nmCRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.
- Division of Urology, Department of Surgery, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan.
- Department of Medicine and Nursing, Hungkuang University, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
ORCID-Profile: Chia-Yen Lin
Zitieren
APA
Huang, P. C., Huang, L. H., Yang, C. K., Li, J. R., Chen, C. S., Wang, S. S., Chiu, K. Y., Ou, Y. C., & Lin, C. Y. (2024). Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective. PLOS ONE. https://doi.org/10.1371/journal.pone.0306900
Vancouver
Huang PC, Huang LH, Yang CK, Li JR, Chen CS, Wang SS, et al. Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective. PLOS ONE. 2024. doi:10.1371/journal.pone.0306900
BibTeX
@article{Huang2024,
author = {Huang, Po-Chieh and Huang, Li-Hua and Yang, Cheng-Kuang and Li, Jian-Ri and Chen, Chuan-Shu and Wang, Shian-Shiang and Chiu, Kun-Yuan and Ou, Yen-Chuan and Lin, Chia-Yen},
title = {Comparative analysis of novel hormonal agents in non-metastatic castration-resistant prostate cancer: A Taiwanese perspective},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0306900}
}
EUVIMED